TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32106302
Drug: Anti-interleukin-6-directed therapies
Normalized name: interleukin-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-interleukin-6-directed therapies in iMCD
Study: 32107674
Drug: General Organizational
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Organizational Index (GOI) scale administered four times over 18 months
Study: 32109839
Drug: Mango polyphenols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mango polyphenols (200-400 g of mango pulp daily for 8 weeks)
Study: 32110025
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate (250-1500 mg/day)
Study: 32110060
Drug: Benralizumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab (30 mg) administered subcutaneously at Days 0, 28, and 56
Study: 32110958
Drug: Study treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment plans (de-intensified radiotherapy)
Study: 32110958
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plans (conventional radiotherapy)
Study: 32111348
Drug: Oral problems
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral problems associated with a low OHRQoL (GOHAI<50)
Study: 32112982
Drug: Crizotinib (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (first-line therapy)
Study: 32113581
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg/day for 4 days)
Study: 32113892
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral agents (DAAs)
Study: 32114500
Drug: TriMixDC-MEL IPI
Normalized name: Mel
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TriMixDC-MEL IPI or subsequent pembrolizumab treatment
Study: 32115672
Drug: VPA +
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA + dextromethorphan (30 mg/day) + memantine (5 mg/day) (DM30 + MM5)
Study: 32115672
Drug: VPA +
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA + dextromethorphan (30 mg/day) (DM30)
Study: 32115672
Drug: VPA +
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA + memantine (5 mg/day) (MM5)
Study: 32116725
Drug: Angusta 25
Normalized name: LAMINARIA ANGUSTATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angusta 25 µg
Study: 32116725
Drug: Cytotec 200
Normalized name: Cytotec 200mcg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotec 200 µg
Study: 32116856
Drug: Family-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based treatment (FBT) with three additional sessions of Intensive Parental Coaching (IPC) after session 4.
Study: 32116856
Drug: Standard Family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Family-based treatment (FBT) without additional IPC.
Study: 32118022
Drug: Plasmalogens treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmalogens treatment, specific dosage and duration not available
Study: 32118616
Drug: Enriched, task-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched, task-specific therapy
Study: 32120379
Drug: QT-prolonging medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: QT-prolonging medications
Study: 32122899
Drug: Cefpirome 2
Normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome 2 g every 8 h for intravenous bolus injection or 2 g every 12 h for extended infusion over 4 h
Study: 32122924
Drug: Tazemetostat (EPZ-6438)
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tazemetostat (EPZ-6438) 800 mg twice a day plus R-CHOP
Study: 32123139
Drug: Other indoor
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other indoor settings (e.g., bar and restaurant)
Study: 32123534
Drug: MVM supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVM supplementation (single dose on Day 1 and 4-week supplementation on Day 28)
Study: 32123534
Drug: MVM supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVM supplementation (single dose on Day 1)
Study: 32125255
Drug: MRI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI with specific absorption rate (SAR) measurements
Study: 32125937
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg per day for 6 months
Study: 32127922
Drug: Early systematic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early systematic supplemental parenteral nutrition (SPN) in combination with nutritional counseling (NC)
Study: 32129861
Drug: 40 mg/kg/day,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg/day, q8h, IV drip 3 h
Study: 32129861
Drug: 80 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/kg/day (continuous infusion)
Study: 32129861
Drug: 160 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/kg/day (continuous infusion)
Study: 32129861
Drug: 20-160 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-160 mg/kg/day
Study: 32130192
Drug: Outsmart HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outsmart HPV content on the Web with monthly unidirectional vaccination reminders sent via text messages
Study: 32130192
Drug: Outsmart HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outsmart HPV content on the Web with monthly interactive vaccination reminders sent via text messages
Study: 32130192
Drug: Standard information
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard information on the Web about HPV vaccine
Study: 32130813
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bedaquiline, pretomanid, and linezolid
Study: 32131742
Drug: Renally inappropriate
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renally inappropriate medications (RIMs)
Study: 32131742
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors and allopurinol
Study: 32131742
Drug: Specific medications
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific medications identified for deprescription
Study: 32133329
Drug: Sedative treatment
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative treatment
Study: 32134216
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of positive PCT, CRP, and DLS values
Study: 32134216
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of negative PCT, CRP, and DLS values
Study: 32138941
Drug: Exposure-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive-behavioral therapy (CBT)
Study: 32139220
Drug: Optimized thienopyridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized thienopyridine treatment for patients with loss-of-function (LOF) alleles (class 2, n = 272)
Study: 32140912
Drug: Inhaled or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled or nasal corticosteroids
Study: 32140912
Drug: CYP3A4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP3A4 inhibitors
Study: 32140912
Drug: CYP3A4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP3A4 inhibitors (specific corticosteroid: beclomethasone)
Study: 32143664
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula therapy at 20, 40, and 60 L/min
Study: 32143664
Drug: Baseline (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (conventional oxygen therapy)
Study: 32144134
Drug: Utomilumab (0.03-10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utomilumab (0.03-10.0 mg/kg every 4 weeks) plus Rituximab (375 mg/m2)
Study: 32145771
Drug: Enasidenib (60-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enasidenib (60-300 mg per day, oral, in repeated 28-day treatment cycles)
Study: 32146304
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg orally twice daily
Study: 32146703
Drug: Zotarolimus-eluting stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotarolimus-eluting stent (ZES) treatment
Study: 32147213
Drug: Intratumoral delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral delivery of plasmid encoding IL-12 (tavokinogene telseplasmid; tavo), 0.5 mg/ml followed by electroporation (six pulses, 1500 V/cm) on days 1, 5, and 8 every 90 days
Study: 32147669
Drug: Dacomitinib (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib (15 mg) plus PD-0325901 (6 mg)
Study: 32147671
Drug: Buparlisib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (80 mg) in combination with imatinib (400 mg)
Study: 32147671
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard therapies)
Study: 32149760
Drug: Before nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before nicorandil medication
Study: 32151247
Drug: Oral antihyperglycemic
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihyperglycemic agents with a blood glucose cut-off value of 3.9 mmol/L (70 mg/dL)
Study: 32151247
Drug: Oral antihyperglycemic
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihyperglycemic agents with a blood glucose cut-off value of 3.0 mmol/L (54 mg/dL)
Study: 32152160
Drug: Early biomarkers
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early biomarkers (albuminuria, N-acetyl-beta-D-glucosaminidase, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin)
Study: 32152173
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous 12/12 human leucocyte antigen-matched sibling cord blood cell infusion
Study: 32153439
Drug: Intense manualized
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense manualized treatment for 1 month as part of the ROCKETLAUNCH project
Study: 32153439
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment in Sweden (data from the 10 previous patients at each outpatient clinic)
Study: 32153804
Drug: Regional and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional and socioeconomic factors, lactation stage, and supplement intake
Study: 32153817
Drug: DDU-supplement (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDU-supplement (500 mg DHA, 10 μg vitamin D)
Study: 32153840
Drug: Patients provided
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients provided medication for nausea as a barrier removal strategy
Study: 32153871
Drug: Cod intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod intake twice weekly for 16 weeks (pregnancy week 20-36)
Study: 32153879
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (3.5 kg corn/soy blended flour with 350 mL vegetable oil every two weeks)
Study: 38966095
Drug: Routine amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine amoxicillin
Study: 32153900
Drug: Daily preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily preventive zinc dispersible tablet
Study: 32153900
Drug: Daily preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily preventive multiple micronutrient powder
Study: 32153900
Drug: Therapeutic zinc
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic zinc dispersible tablet for diarrhea
Study: 32153947
Drug: 40 g lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g lipid-based nutrient supplement (Epi-E)
Study: 32153959
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (30,000 IU weekly for 6 months)
Study: 32154497
Drug: ULT (Iron-Enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: ULT (Iron-Enriched Supplement)
Study: 32156630
Drug: IXIARO® Japanese
Approvals — FDA: no, EMA: no, PMDA: no
Description: IXIARO® Japanese encephalitis vaccine (2-dose primary series)
Study: 32156743
Drug: Tirabrutinib monotherapy
Normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirabrutinib monotherapy (80 mg every day)
Study: 32156743
Drug: Tirabrutinib in
Normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirabrutinib in combination with Idelalisib (50 mg twice a day or 100 mg every day)
Study: 32156743
Drug: Tirabrutinib in
Normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirabrutinib in combination with Entospletinib (200 mg or 400 mg every day)
Study: 32157590
Drug: Telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telotristat ethyl treatment
Study: 32158272
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin and statins offered to men with AAA after the millennium (VIVA and DANCAVAS trials)
Study: 32160294
Drug: Ruxolitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (5 mg twice daily plus corticosteroids)
Study: 32161584
Drug: Adjuvant ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjuvant ipilimumab co-administration with a peptide vaccine
Study: 32161660
Drug: KAPA intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KAPA intervention (six group sessions of motivational interviewing, monthly)
Study: 32161846
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) infusions, initially every 4 weeks, then extended to every 6 weeks for the first 3 months, with subsequent intervals determined by the clinician
Study: 32163431
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy Text Messaging Intervention
Study: 32164435
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion during exercise testing
Study: 32164981
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with cytotoxic chemotherapy (4 cycles)
Study: 32165096
Drug: FOLFOX-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-based therapy
Study: 32167861
Drug: Bemarituzumab (FPA144)
Normalized name: Bemarituzumab
DrugBank: Bemarituzumab (DB16105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemarituzumab (FPA144) at doses of 0.3 to 15 mg/kg every 2 weeks
Study: 32167861
Drug: Bemarituzumab (FPA144)
Normalized name: Bemarituzumab
DrugBank: Bemarituzumab (DB16105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemarituzumab (FPA144) at doses of ≥ 10 mg/kg every 2 weeks for ≥ 70 days
Study: 32168224
Drug: HCV antibody
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV antibody positive women (case group)
Study: 32168224
Drug: HCV antibody
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV antibody negative women (control group)
Study: 32168240
Drug: Silicone-hydrogel daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone-hydrogel daily disposable contact lenses (delefilcon A)
Study: 32168240
Drug: Hydrogel daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel daily disposable contact lenses (omafilcon A)
Study: 32169783
Drug: Durvalumab (Du)
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab (Du) 1500 mg every 3 weeks (q3w)
Study: 32169783
Drug: Tremelimumab (Tr)
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (Tr) 75 mg q3w for 5 doses
Study: 32169783
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Du and Tr with platinum-doublet chemotherapy
Study: 32169783
Drug: Chemotherapy (pemetrexed,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed, gemcitabine, etoposide, nab-paclitaxel with cisplatin or carboplatin)
Study: 32169872
Drug: hu14.18K322A mAb
Approvals — FDA: no, EMA: no, PMDA: no
Description: hu14.18K322A mAb treatment
Study: 32170554
Drug: Gefitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib plus chemotherapy (pemetrexed plus carboplatin)
Study: 32171061
Drug: MOR202 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR202 monotherapy (0.01 mg/kg to 16 mg/kg)
Study: 32171069
Drug: Venetoclax (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (360 mg/m) in combination with chemotherapy
Study: 32171069
Drug: Venetoclax (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (240 mg/m) during dose escalation
Study: 32171104
Drug: S-1 (80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (80-120 mg/day on days 1-14) and oxaliplatin (130 mg/m2) followed by surgery
Study: 32172489
Drug: BI 836826
Normalized name: BI 836826
DrugBank: BI-836826 (DB17322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 836826 (CD37 antibody) at doses ranging from 1 mg to 200 mg, with a maximum tolerated dose (MTD) of 100 mg; administered as an intravenous infusion once weekly for 4 weeks.
Study: 32173192
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with iliac leg endoprosthesis without coverage of the hypogastric artery
Study: 32174840
Drug: No asthma
Approvals — FDA: no, EMA: no, PMDA: no
Description: No asthma treatment
Study: 32175519
Drug: small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: small-quantity lipid-based nutrition supplement (LNS) containing >20 micronutrients
Study: 32175617
Drug: Chimeric antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor T-cell therapies (CAR T-cells)
Study: 32175617
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation trials
Study: 32175969
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of adverse drug events (ADEs) by clinical pharmacists through structured interviews and medication history collection.
Study: 32176787
Drug: Imipenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (1 g mixed with 200 mL normal saline, infused intravenously over 3 hours at 8-hour intervals, concentration 5 mg/mL, rate of infusion 5.5 mg/min)
Study: 32178626
Drug: L-arginine/ADMA ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine/ADMA ratio assessment at 4-24 hours after surgery
Study: 32178676
Drug: Polyacrylamide gel
Normalized name: polyacrylamide (10000 MW)
DrugBank: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide) (DB14771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyacrylamide gel electrophoresis Lipoprint© System for lipoprotein profile analysis
Study: 32179633
Drug: Spartalizumab (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spartalizumab (1, 3, or 10 mg/kg Q2W; 3 or 5 mg/kg Q4W)
Study: 32182364
Drug: Intralesional rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intralesional rituximab (4 weekly injections followed by 6 monthly injections)
Study: 32182791
Drug: Everolimus at
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus at 10 mg/day
Study: 32182791
Drug: Everolimus at
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus at 10 mg/day with octreotide LAR at 30 mg/month (18 patients)
Study: 32182949
Drug: Curative intent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Curative intent radiotherapy with or without androgen deprivation therapy (ADT)
Study: 32183229
Drug: Zebrafish avatar
Normalized name: ZINC OXIDE 20 g in 100 g TOPICAL LOTION [avatara Kom Bu Cha The Simple Shield Balancing Oil-Free Moisturizer SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zebrafish avatar model for drug efficacy studies
Study: 32183229
Drug: Chemotherapy dose
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy dose conversion formula
Study: 32184653
Drug: Standard analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesic treatment (SAT; IV paracetamol 1g or ketoprofen 100mg for moderate pain [NRS 4-6] and IV morphine 0.1mg/kg for severe pain [NRS ≥7])
Study: 32185745
Drug: Repository Corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository Corticotropin Injection (RCI) 80 U twice weekly for 12 weeks
Study: 32186413
Drug: Herbal Medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal Medicine SH003
Study: 32187112
Drug: BUP-XR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP-XR treatment duration >12 months
Study: 32187112
Drug: BUP-XR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP-XR treatment duration ≤2 months
Study: 32187112
Drug: BUP-XR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP-XR treatment